"The Federal Circuit has affirmed U.S. District Judge Brian Martinotti‘s finding that Opiant Pharmaceuticals‘ patents on opioid overdose treatment Narcan are invalid as obvious. Sterne Kessler Goldstein & Fox partner J.C. Rozendaal piloted Teva Pharmaceuticals to the 2-1 decision in Adapt Pharma v. Teva Pharmaceuticals. Majority author Kara Stoll acknowledged it was “a close case, with facts supporting both parties’ arguments as to their preferred outcome.” Judge Pauline Newman dissented, saying that Opiant had solved unmet need by creating an intranasal version of naloxone."
The Sterne, Kessler, Goldstein & Fox team representing Teva was led by J.C. Rozendaal, director and chair of the firm’s Trial & Appellate Group, and includes fellow Directors: Paul Ainsworth, Michael Joffre, Adam LaRock, William Milliken, and Chandrika Vira.
To read the full article, please click the link below.